Siplizumab (MEDI-507) 是一种抗CD2的人源化 IgG1 单克隆抗体。Siplizumab 可耗尽 T 细胞、降低 T 细胞活化、抑制 T 细胞增殖并富集naive和bona fide调节性 T 细胞。
| 生物活性 | Siplizumab (MEDI-507) is a humanizedIgG1monoclonal antibody againstCD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enrichesnaiveandbona fideregulatory T cells[1]. |
体外研究
(In Vitro) | Siplizumab (MEDI-507; 0.00001-10 nM) 结合 FcγR 并诱导信号转导[1]。
Siplizumab (0.0001-10 μg/mL) 介导细胞耗竭并降低 T 细胞增殖[1]。
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com